CompletedPhase 2

OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

68 participantsStarted 2014-03

Plain-language summary

The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Has a positive history of ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen * Has a positive bilateral CAC reaction to a perennial allergen within minutes of instillation Exclusion Criteria: * History of ocular surgical intervention within the past 3 months * Presence of an active ocular infection or positive history of an ocular herpetic infection at any visit * Use any of the following disallowed medications during the period indicated

What they're measuring

Ocular Itching

Timeframe: 14 days post insertion

Trial details

NCT IDNCT02062905

SponsorOcular Therapeutix, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-08

Results submitted2016-02-29

View on ClinicalTrials.gov More Chronic Allergic Conjunctivitis trials